AstraZeneca inks $730m licensing deal for rare heart disease treatment

11-01-2022

Muireann Bolger

AstraZeneca inks $730m licensing deal for rare heart disease treatment

Mats Wiklund / Shutterstock.com

Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy (ATTR-CM).


AstraZeneca, heart disease, licensing agreement, Alexion, antibodies, Neurimmune, patents

LSIPR